Simon C Robson Selected Research

Apyrase (ATP Diphosphatase)

7/2020	Modulation of CD39 and Exogenous APT102 Correct Immune Dysfunction in Experimental Colitis and Crohn's Disease.
9/2017	Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease.
1/2015	CD39 improves survival in microbial sepsis by attenuating systemic inflammation.
8/2014	Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
6/2012	Overexpression of NTPDase2 in gliomas promotes systemic inflammation and pulmonary injury.
5/2012	P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice.
4/2010	SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning.
8/2009	Selective NTPDase2 expression modulates in vivo rat glioma growth.
10/2007	CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury.
9/2007	Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Simon C Robson Research Topics

Disease

52	Inflammation (Inflammations) 01/2021 - 04/2002
35	Neoplasms (Cancer) 01/2022 - 01/2007
18	Reperfusion Injury 01/2022 - 03/2004
15	Fibrosis (Cirrhosis) 01/2020 - 01/2008
14	Thrombosis (Thrombus) 01/2021 - 04/2002
12	Vascular System Injuries 03/2014 - 03/2004
11	Colitis 11/2020 - 04/2005
10	Ischemia 01/2014 - 03/2004
9	Hypoxia (Hypoxemia) 07/2020 - 09/2003
7	Liver Cirrhosis (Hepatic Cirrhosis) 10/2021 - 01/2016
7	Sepsis (Septicemia) 10/2017 - 10/2008
7	Thrombocytopenia (Thrombopenia) 09/2014 - 01/2005
6	Crohn Disease (Crohn's Disease) 11/2020 - 05/2011
6	Neoplasm Metastasis (Metastasis) 01/2020 - 06/2011
6	Hepatitis 01/2019 - 09/2008
6	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 10/2012
6	Myocardial Infarction 01/2018 - 11/2005
5	Non-alcoholic Fatty Liver Disease 10/2021 - 01/2013
5	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2019 - 04/2005
5	Hemorrhage 09/2014 - 07/2003
4	Pneumonia (Pneumonitis) 01/2021 - 01/2016
4	Infections 01/2019 - 06/2003
4	Infarction (Infarctions) 08/2014 - 10/2007
4	Colonic Neoplasms (Colon Cancer) 04/2013 - 06/2007
3	Insulin Resistance 03/2016 - 09/2008
3	Pathologic Processes 01/2016 - 01/2005
3	Lung Injury 12/2015 - 06/2012
3	Thrombotic Microangiopathies 11/2015 - 07/2003
3	Necrosis 03/2015 - 08/2008
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2012 - 10/2007
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 04/2013
2	Melanoma (Melanoma, Malignant) 01/2022 - 12/2012
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 01/2021
2	Autoimmune Hepatitis 01/2021 - 06/2012
2	Diabetic Nephropathies (Diabetic Nephropathy) 01/2018 - 09/2007

Drug/Important Bio-Agent (IBA)

34	Adenosine (Adenocard)FDA LinkGeneric 01/2022 - 09/2003
34	Adenosine Triphosphate (ATP)IBA 01/2022 - 04/2002
25	NucleotidesIBA 01/2021 - 04/2002
14	triphosphoric acid (triphosphate)IBA 01/2021 - 04/2002
12	Adenosine Diphosphate (ADP)IBA 10/2021 - 04/2002
12	NucleosidesIBA 12/2018 - 04/2002
11	Apyrase (ATP Diphosphatase)IBA 07/2020 - 03/2004
11	EnzymesIBA 01/2018 - 12/2008
9	Purinergic Receptors (Receptors, Purine)IBA 01/2021 - 11/2006
9	CytokinesIBA 01/2020 - 01/2008
9	Proteins (Proteins, Gene)FDA Link 01/2017 - 06/2003
7	ectoATPaseIBA 08/2020 - 03/2006
7	Messenger RNA (mRNA)IBA 01/2016 - 09/2003
6	5'-Nucleotidase (5' Nucleotidase)IBA 01/2022 - 12/2004
6	Biological ProductsIBA 01/2022 - 01/2005
6	CD39 antigenIBA 10/2021 - 10/2007
6	Dextran SulfateIBA 07/2020 - 11/2005
6	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2019 - 11/2006
5	Adenosine Monophosphate (AMP)IBA 10/2021 - 12/2004
5	Oxygen (Dioxygen)IBA 01/2021 - 09/2003
5	SodiumIBA 01/2019 - 05/2011
5	Biomarkers (Surrogate Marker)IBA 07/2018 - 10/2011
4	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2021 - 06/2015
4	InflammasomesIBA 01/2020 - 01/2014
4	MicroRNAs (MicroRNA)IBA 07/2018 - 10/2012
4	Interleukin-10 (Interleukin 10)IBA 01/2018 - 08/2008
4	Dextrans (Dextran)FDA Link 09/2017 - 04/2005
4	Pharmaceutical PreparationsIBA 01/2017 - 04/2008
4	Adenine NucleotidesIBA 01/2016 - 09/2003
3	Adenosine DeaminaseIBA 10/2021 - 10/2014
3	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 10/2021 - 07/2012
3	Therapeutic UsesIBA 07/2020 - 01/2018
3	CollagenIBA 01/2019 - 01/2008
3	purineIBA 01/2019 - 12/2008
3	3,5- diethoxycarbonyl- 1,4- dihydrocollidineIBA 01/2019 - 11/2017
3	Thromboplastin (Tissue Factor)IBA 01/2018 - 04/2006
3	LipidsIBA 01/2018 - 01/2013
3	Purinergic P2X7 ReceptorsIBA 10/2017 - 05/2013
3	AnticoagulantsIBA 05/2017 - 11/2005
3	Blood Coagulation Factors (Coagulation Factor)IBA 05/2017 - 06/2003
3	VLDL LipoproteinsIBA 03/2016 - 01/2013
3	Lipoproteins (Lipoprotein)IBA 01/2016 - 01/2013
3	Triglycerides (Triacylglycerol)IBA 01/2014 - 06/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2013 - 10/2008
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2012 - 07/2003
2	Interleukin-27 (Interleukin 27)IBA 01/2022 - 10/2013
2	PurinesIBA 01/2021 - 01/2020
2	Sulfonic AcidsIBA 11/2020 - 05/2011
2	Deferoxamine (Desferal)FDA LinkGeneric 07/2020 - 04/2005
2	Interleukin-2 (IL2)IBA 01/2020 - 01/2019
2	Purinergic P1 Receptor AntagonistsIBA 01/2019 - 07/2012
2	LigandsIBA 11/2018 - 09/2017
2	BilirubinIBA 11/2018 - 05/2017
2	AngiopoietinsIBA 07/2018 - 07/2016
2	SaltsIBA 01/2018 - 07/2012

Therapy/Procedure

24	Therapeutics 01/2022 - 07/2003
12	Transplantation 01/2021 - 05/2004
8	Heterologous Transplantation (Xenotransplantation) 01/2022 - 06/2003
6	Liver Transplantation 01/2019 - 11/2005
4	Drug Therapy (Chemotherapy) 01/2022 - 04/2008
4	Ligation 11/2018 - 10/2008
3	Immunotherapy 01/2022 - 01/2017
3	Punctures 10/2017 - 10/2008
2	Artificial Respiration (Mechanical Ventilation) 01/2021 - 12/2017
2	Aftercare (After-Treatment) 01/2019 - 12/2015